ATE224396T1 - N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine - Google Patents

N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine

Info

Publication number
ATE224396T1
ATE224396T1 AT95924657T AT95924657T ATE224396T1 AT E224396 T1 ATE224396 T1 AT E224396T1 AT 95924657 T AT95924657 T AT 95924657T AT 95924657 T AT95924657 T AT 95924657T AT E224396 T1 ATE224396 T1 AT E224396T1
Authority
AT
Austria
Prior art keywords
indole
purine
substituted
pyrimidine
derivatives
Prior art date
Application number
AT95924657T
Other languages
English (en)
Inventor
Bradley J Benson
Xiannong Chen
George J Cianciolo
Jose-Luis Diaz
Khalid S Ishaq
Susan L Morris-Natschke
Ronald J Uhing
Henry Wong
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE224396T1 publication Critical patent/ATE224396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT95924657T 1994-06-22 1995-06-21 N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine ATE224396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/264,039 US5643893A (en) 1994-06-22 1994-06-22 N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
PCT/US1995/007936 WO1995035300A1 (en) 1994-06-22 1995-06-21 N-substituted-(dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines

Publications (1)

Publication Number Publication Date
ATE224396T1 true ATE224396T1 (de) 2002-10-15

Family

ID=23004300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95924657T ATE224396T1 (de) 1994-06-22 1995-06-21 N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine

Country Status (16)

Country Link
US (1) US5643893A (de)
EP (1) EP0767793B1 (de)
JP (1) JP3805789B2 (de)
KR (1) KR970703975A (de)
AT (1) ATE224396T1 (de)
AU (1) AU2907795A (de)
CA (1) CA2193644A1 (de)
DE (1) DE69528267T2 (de)
DK (1) DK0767793T3 (de)
ES (1) ES2183877T3 (de)
FI (1) FI965141A7 (de)
HU (1) HUT76298A (de)
NO (1) NO965521L (de)
NZ (1) NZ289286A (de)
PT (1) PT767793E (de)
WO (1) WO1995035300A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295811A1 (en) * 1997-07-15 1999-01-20 Japan Energy Corporation Novel purine derivatives and their use as medicines
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
AU774492B2 (en) 1999-07-22 2004-07-01 Celmed Oncology (Usa) Inc. Methods for treating therapy-resistant tumors
US6586429B2 (en) 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
EP1359921A4 (de) * 2001-01-19 2006-09-06 Newbiotics Inc Verfahren zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
US20030022864A1 (en) * 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) * 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004071383A2 (en) * 2003-02-11 2004-08-26 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
EP1651198A2 (de) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selektive pharmakologische hemmung des protein-verkehrs und verwandte verfahren zur behandlung von erkrankungen beim menschen
MY146066A (en) * 2004-07-01 2012-06-29 Microlin L C Device employing gas generating cell for facilitating controlled release of fluid into ambient environment
US20090264384A1 (en) * 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
WO2006050236A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
US20090005344A1 (en) * 2004-11-01 2009-01-01 Nkuada, Llc Compounds and Methods of Use Thereof
WO2007134169A2 (en) * 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20080269204A1 (en) * 2004-11-01 2008-10-30 Tatyana Dyakonov Compounds and Methods of Use Thereof
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
US8853185B2 (en) * 2008-04-09 2014-10-07 Cornell University Coferons and methods of making and using them
TW201000107A (en) * 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CA2757622A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2011043817A1 (en) 2009-10-07 2011-04-14 Cornell University Coferons and methods of making and using them
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
EP2647639A1 (de) * 2012-04-06 2013-10-09 LEK Pharmaceuticals d.d. ß-boration Alken- und Alkyn-Zwischenstoffen
DK3362462T3 (da) 2015-10-12 2021-10-11 Advanced Cell Diagnostics Inc In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil
CA3266666A1 (en) 2022-09-07 2024-03-14 Mdx Management Llc SHP-1 INHIBITORS FOR CANCER TREATMENT
AU2023373917A1 (en) 2022-11-02 2025-05-01 Mdx Management Llc Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
KR20260016906A (ko) 2023-03-17 2026-02-04 엠디엑스 메니지먼트 엘엘씨 요법의 유해효과를 개선하기 위한 조성물 및 방법
WO2025038745A1 (en) 2023-08-16 2025-02-20 Mdx Management Llc Compositions and methods for activating immune cells
WO2025188914A1 (en) 2024-03-06 2025-09-12 Mdx Management Llc Tyrosine phosphatase inhibitor 1 (tpi-1) derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
GB8926611D0 (en) * 1989-11-24 1990-01-17 Xenova Ltd Compound and its use
US5130302A (en) * 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5362732A (en) * 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
DE69332634T2 (de) * 1992-03-04 2003-05-08 Cell Therapeutics, Inc. Enantiomere hydroxylierte xanthinverbindungen
US5306722A (en) * 1992-09-02 1994-04-26 Bristol-Myers Squibb Company Thymidine derivatives and therapeutic method of use

Also Published As

Publication number Publication date
JP3805789B2 (ja) 2006-08-09
DK0767793T3 (da) 2002-10-14
HUT76298A (en) 1997-07-28
ES2183877T3 (es) 2003-04-01
EP0767793A1 (de) 1997-04-16
FI965141A0 (fi) 1996-12-20
HU9603536D0 (en) 1997-02-28
AU2907795A (en) 1996-01-15
NZ289286A (en) 1998-09-24
FI965141L (fi) 1996-12-20
DE69528267D1 (de) 2002-10-24
US5643893A (en) 1997-07-01
EP0767793B1 (de) 2002-09-18
WO1995035300A1 (en) 1995-12-28
DE69528267T2 (de) 2003-04-17
NO965521L (no) 1997-02-21
KR970703975A (ko) 1997-08-09
PT767793E (pt) 2003-02-28
CA2193644A1 (en) 1995-12-28
NO965521D0 (no) 1996-12-20
JPH10507739A (ja) 1998-07-28
FI965141A7 (fi) 1996-12-20

Similar Documents

Publication Publication Date Title
ATE224396T1 (de) N-substituierte-dihydroxyborylalkyl derivate von purin, indol und pyrimidin, geeignet als inhibitore von entzündliche cytokine
ATE186545T1 (de) Hydroxyalkylammonium-pyrimidine und purine und nukleosidderivate zur inhibierung entzündlicher cytokine
DK0790997T3 (da) 6-Aryl-pyrido[2,3-d]pyrimidiner og napthyridiner til hæmning af protein-tyrosin-kinase-fremkaldt celleproliferation
DK1109785T3 (da) Indolderivater og deres anvendelse til behandling af ondartede og andre sygdomme forårsaget af patologisk celleproliferation
EA199700356A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИНЫ ДЛЯ ИНГИБИРОВАНИЯ ОПОСРЕДОВАННОЙ ПРОТЕИНТИРОЗИНКИНАЗЫ КЛЕТОЧНОЙ ПРОЛИФЕРАЦИИ
EA200201096A1 (ru) СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
NO952398D0 (no) Pyrrolpyrimidiner som CRF antagonister
DE60314639D1 (de) Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
SI1070056T1 (en) Phthalazinone pde iii/iv inhibitors
TR199802385T2 (xx) TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
BG100137A (bg) Аналози на сиалил lе горе х като инхибитори на клетъчната адхезия
ATE242245T1 (de) Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
ATE242234T1 (de) Bicyclische arylcarboxamide und ihre therapeutische verwendung
SE9702773D0 (sv) Novel compounds
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
ATE305787T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE209187T1 (de) Fluorinierte 2-nitroimidazole analoge zur detektion von hypoxischen tumorzellen
ATE302772T1 (de) 2-(1h-indol-3-yl)-2-oxo-acetamide mit antitumoraler wirkung
DE60015945D1 (en) 2-hydroxy methylcyclopropylidenmethylpurine als antivirale wirkstoffe
DE60008400D1 (de) Triazolopyrimidinderivate
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
EA200101096A1 (ru) Применение производных мадурафталазина в качестве ингибиторов провоспалительных цитокинов
IT1313593B1 (it) Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0767793

Country of ref document: EP

REN Ceased due to non-payment of the annual fee